Organic electroluminescent materials and devices
US-2021070792-A1 · Mar 11, 2021 · US
Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use
US11718617B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11718617-B2 |
| Application number | US-202218072497-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 30, 2022 |
| Priority date | May 4, 2020 |
| Publication date | Aug 8, 2023 |
| Grant date | Aug 8, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from: Ex. 3 Ex. 19 Ex. 22 Ex 23 Ex. 28 Ex. 49 Ex. 61 Ex. 77 Ex. 82 Ex. 94 Ex. 107 Ex. 117 Ex. 123 Ex. 124 Ex. 125 Ex. 126 Ex. 128 Ex. 129 Ex. 131 Ex. 133 Ex. 136 Ex. 137 Ex. 146 Ex. 149 Ex. 150 Ex. 151
Assignees
Inventors
Classifications
- C07D519/00Primary
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11718617B2 cover?
- The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthes…
- Who is the assignee on this patent?
- Amgen Inc, Vigil Neuroscience Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D519/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).